In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey.
Margo OlbrechtFedoua EchahidiDenis PiérardCharlotte PeetersPeter VandammeIngrid WyboThomas DemuyserPublished in: Antimicrobial agents and chemotherapy (2023)
We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.
Keyphrases
- gram negative
- multidrug resistant
- cystic fibrosis
- end stage renal disease
- genetic diversity
- ejection fraction
- newly diagnosed
- klebsiella pneumoniae
- chronic kidney disease
- acinetobacter baumannii
- drug resistant
- escherichia coli
- prognostic factors
- pseudomonas aeruginosa
- cross sectional
- lung function
- patient reported outcomes
- microbial community
- wastewater treatment
- chronic obstructive pulmonary disease